Basilea CEO Ronald Scott offered that the next best step for the biotech may be to just sell the Basel-based company to a U.S.-based biopharma company interested in a quick tax inversion deal that would allow a buyer the chance of trading American taxes for a sweeter deal in Switzerland.

…read more

Source: Prefer a Swiss tax rate? Basilea chief says he’s ready to parley


0 No comments